中晚期宫颈鳞癌患者治疗前外周血Treg计数分析

郑雨薇; 黄啸; 郭林

doi:10.3969/j.issn.1007-3969.2015.04.001

您当前的位置：

首页 >

文章列表页 >

中晚期宫颈鳞癌患者治疗前外周血Treg计数分析

更新时间：2025-12-31

- 中晚期宫颈鳞癌患者治疗前外周血Treg计数分析
- Pre-treatment circulating regulatory T cell count analysis of advanced cervical squamous cell carcinoma patients
- 中国癌症杂志 2015年25卷第4期页码：241-246
- 作者机构：
  
  1. 复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系,上海,200032
  2. 复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系,上海,200032
  3. 复旦大学附属肿瘤医院检验科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
  
  国家自然科学基金青年科学基金资助项目(81101956/H1621)。
- DOI：10.3969/j.issn.1007-3969.2015.04.001
  中图分类号：
- 网络出版：2015-05-25，
  
  纸质出版：2015-05-25
- 稿件说明：
移动端阅览
郑雨薇,黄啸,郭林,等. 中晚期宫颈鳞癌患者治疗前外周血Treg计数分析[J]. 中国癌症杂志, 2015, 25(4): 241-246.

郑雨薇, 黄啸, 郭林. Pre-treatment circulating regulatory T cell count analysis of advanced cervical squamous cell carcinoma patients[J]. China Oncology, 2015, 25(4): 241-246.
郑雨薇,黄啸,郭林,等. 中晚期宫颈鳞癌患者治疗前外周血Treg计数分析[J]. 中国癌症杂志, 2015, 25(4): 241-246. DOI： 10.3969/j.issn.1007-3969.2015.04.001.

郑雨薇, 黄啸, 郭林. Pre-treatment circulating regulatory T cell count analysis of advanced cervical squamous cell carcinoma patients[J]. China Oncology, 2015, 25(4): 241-246. DOI： 10.3969/j.issn.1007-3969.2015.04.001.

摘要

背景与目的：中晚期宫颈鳞癌同期放化疗(concurrent chemoradiotherapy，CCRT)治疗前性价比高的疗效判断方法较有限，该研究拟通过检测治疗前外周血CD4

CD25

CD127

Low/-

调节性T细胞(regulatory T cells，Tregs)亚群计数及血清鳞癌抗原(squamous cell carcinoma antigen，SCC-Ag)水平，评价两者预测临床疗效的可行性。方法：采集44例Ⅱ

~Ⅳ

期宫颈鳞癌患者行CCRT治疗前的外周血标本，分别利用流式细胞免疫表型分析和酶联免疫法检测外周血CD4

CD25

CD127

Low/-

Treg计数及血清SCC-Ag水平。收集临床和病理资料，并统计检验2个指标对疗效的预测作用。结果：治疗前外周血CD4

CD25

CD127

Low/-

Treg计数在临床有效组低于无效组［(8.78±2.80)% vs (10.95±2.56)%，P0.05］，血清SCC-Ag在不同临床疗效组间差异无统计学意义，且这2个、指标之间未发现相关性(Spearman’rho=-0.093，P=0.540)。经受试者工作特征(receiver operating characteristic，ROC)曲线确定治疗前外周血CD4

CD25

CD127

Low/-

Treg及血清SCC-Ag最佳界值分别为9.76%与9.50 ng/mL。单因素分析显示，治疗前外周血CD4

CD25

CD127

Low/-

Treg计数(OR=1.901，95%CI：1.112~3.219，P=0.017)对CCRT疗效有预测作用，而血清SCC-Ag水平无预测作用(OR=0.998，95%CI：0.001~4.253，P=0.897)。多因素Logistic回归分析显示，治疗前外周血CD4

CD25

CD127

Low/-

Treg为独立的临床疗效预测因子(OR=3.115，95%CI：1.253~7.742，P=0.014)。结论：治疗前外周血CD4

CD25

CD127

Low/-

Treg计数用于中晚期宫颈鳞癌患者CCRT临床疗效预测具有可行性。

Abstract

Background and purpose: Due to the lack of cos

t-effective pre-treatment predictors for advanced cervical squamous cell carcinomas treated with concurrent chemoradiotherapy (CCRT)

both baseline circulating CD4

CD25

CD127

Low/-

regulatory T cell (Treg) count and serum squamous cell carcinoma antigen (SCC-Ag) level were measured for this feasibility study. Methods: Peripheral blood samples were collected from 44 patients with stage Ⅱ

-Ⅳ

cervical squamous carcinomas before CCRT. Flow cytometry immunophenotyping and enzyme-linked immunosorbent assay were used for circulating CD4

CD25

CD127

Low/-

Treg count and serum SCC-Ag level testing

respectively. Clinical and pathological characteristics were retrospectively reviewed to analyze the predictive value of the 2 indexes. Results: The baseline circulating CD4

CD25

CD127

Low/-

Treg count was lower in the patient group with positive treatment response than in the group with negative response ［(8.78±2.80)% vs (10.95±2.56)%

P0.05］

and the serum SCC-Ag level showed no significant difference between the 2 groups. No correlation was detected between these 2 markers (Spearman’rho=-0.093

P=0.540). Determined by plotting receiver operating characteristic curves

the best cut-off points were 9.76% for circulating CD4

CD25

CD127

Low/-

Treg count and 9.50 ng/mL for serum SCCAg level

respectively. Univariate analysis showed that pretherapeutic circulating CD4

CD25

CD127

Low/-

Treg count (OR=1.901

95%CI: 1.112-3.219

P=0.017)

but not serum SCC-Ag level (OR=0.998

95%CI: 0.001-4.253

P=0.897)

was predictive of clinical response to CCRT. Multivariate Logistic regression analysis revealed that pre-treatment CD4

CD25

CD127

Low/-

Treg count was an independent predictor for clinical response to CCRT (OR=3.115

95%CI: 1.253-7.742

P=0.014). Conclusion: Pretherapeutic circulating CD4

CD25

CD127

Low/-

Treg count is a feasible method to predict clinical response to CCRT in patients with advanced cervical squamous cell carcinomas.

关键词

Keywords

references

浏览量

1658

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

口服营养补充对鼻咽癌同期放化疗患者的影响

TPF诱导化疗或PF诱导化疗联合同期放化疗治疗局部晚期鼻咽癌的临床观察

局部晚期头颈部鳞癌的靶向治疗进展